{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T22:17:08Z","timestamp":1789510628837,"version":"build-2803163510"},"reference-count":56,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014461","name":"The National Institute for Health Research Biomedical Research Centre for cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014461","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","redjournal.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.ijrobp.2024.07.2317","type":"journal-article","created":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T00:41:15Z","timestamp":1722040875000},"page":"165-175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Bladder Tumor-Focused Adaptive Radiation Therapy: Clinical Outcomes of a Phase I Dose Escalation Study"],"prefix":"10.1016","volume":"121","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2057-0946","authenticated-orcid":false,"given":"Shaista","family":"Hafeez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karole","family":"Warren-Oseni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kabir","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"El-Ghzal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dearnaley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atia","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pardeep","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Lalondrelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen A.","family":"McNair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vibeke N.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Huddart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2024.07.2317_bib0001","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: Summary of the 2020 guidelines","volume":"79","author":"Witjes","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2024.07.2317_bib0002","unstructured":"National Comprehensive Cancer Network. NCCN Guidelines. version 1. 2023. Muscle invasive bladder cancer. 2023. Accessed February 19, 2023. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf"},{"key":"10.1016\/j.ijrobp.2024.07.2317_bib0003","unstructured":"National Institute for Health and Clinical Excellence (NICE) Guidance. Bladder cancer: Diagnosis and management. 2015. Accessed February 19, 2023. http:\/\/wwwniceorguk\/guidance\/ng2\/evidence\/full-guideline"},{"key":"10.1016\/j.ijrobp.2024.07.2317_bib0004","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","article-title":"Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: A multi-institutional propensity score matched and weighted analysis","volume":"24","author":"Zlotta","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2024.07.2317_bib0005","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.1996.14.11.2901","article-title":"Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group","volume":"14","author":"Coppin","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.07.2317_bib0006","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa1106106","article-title":"Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer","volume":"366","author":"James","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2024.07.2317_bib0007","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.radonc.2016.09.006","article-title":"Concurrent gemcitabine and radiotherapy for the treatment of muscle-invasive bladder cancer: A pooled individual data analysis of eight phase I-II trials","volume":"121","author":"Caffo","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2024.07.2317_bib0008","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.eururo.2014.02.038","article-title":"Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: A systematic review","volume":"66","author":"Ploussard","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2024.07.2317_bib0009","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1200\/JCO.2010.28.4950","article-title":"Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma","volume":"28","author":"Hoskin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.07.2317_bib0010","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.eururo.2022.04.017","article-title":"Chemoradiotherapy in muscle-invasive bladder cancer: 10-yr follow-up of the phase 3 randomised controlled BC2001 trial","volume":"82","author":"Hall","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2024.07.2317_bib0011","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/JU.0000000000001696","article-title":"Complications and outcomes of salvage cystectomy after trimodality therapy","volume":"206","author":"Pieretti","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.ijrobp.2024.07.2317_bib0012","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0090-4295(01)01219-5","article-title":"Selective bladder conservation using transurethral resection, chemotherapy, and radiation: Management and consequences of Ta, T1, and Tis recurrence within the retained bladder","volume":"58","author":"Zietman","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.ijrobp.2024.07.2317_bib0013","doi-asserted-by":"crossref","first-page":"e421","DOI":"10.1016\/j.clon.2022.05.003","article-title":"Mapping local failure following bladder radiotherapy according to dose","volume":"34","author":"Abdel-Aty","year":"2022","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.ijrobp.2024.07.2317_bib0014","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ijrobp.2004.02.056","article-title":"Clinical radiobiology of stage T2-T3 bladder cancer","volume":"60","author":"Majewski","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.07.2317_bib0015","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.ijrobp.2005.09.023","article-title":"Radical radiotherapy for invasive bladder cancer: What dose and fractionation schedule to choose?","volume":"64","author":"Pos","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.07.2317_bib0016","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.eururo.2012.08.009","article-title":"ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder","volume":"63","author":"Gakis","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2024.07.2317_bib0017","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1200\/JCO.2008.19.5776","article-title":"Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06","volume":"27","author":"Efstathiou","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.07.2317_bib0018","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0360-3016(91)90171-Y","article-title":"Tolerance of normal tissue to therapeutic irradiation","volume":"21","author":"Emami","year":"1991","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.07.2317_bib0019","doi-asserted-by":"crossref","first-page":"S116","DOI":"10.1016\/j.ijrobp.2009.02.090","article-title":"Radiation dose-volume effects of the urinary bladder","volume":"76","author":"Viswanathan","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.07.2317_bib0020","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ijrobp.2013.06.2044","article-title":"Randomized noninferiority trial of reduced high-dose volume versus standard volume radiation therapy for muscle-invasive bladder cancer: results of the BC2001 trial (CRUK\/01\/004)","volume":"87","author":"Huddart","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.07.2317_bib0021","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ijrobp.2003.10.018","article-title":"Radiotherapy for muscle-invasive carcinoma of the bladder: Results of a randomized trial comparing conventional whole bladder with dose-escalated partial bladder radiotherapy","volume":"59","author":"Cowan","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.07.2317_bib0022","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.clon.2021.03.023","article-title":"Image-guided adaptive radiotherapy for bladder cancer","volume":"33","author":"Kong","year":"2021","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.ijrobp.2024.07.2317_bib0023","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.ijrobp.2009.12.003","article-title":"Adaptive-predictive organ localization using cone-beam computed tomography for improved accuracy in external beam radiotherapy for bladder cancer","volume":"79","author":"Lalondrelle","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.07.2317_bib0024","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.ijrobp.2006.07.013","article-title":"Online adaptive radiotherapy of the bladder: Small bowel irradiated-volume reduction","volume":"66","author":"Burridge","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.07.2317_bib0025","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.clon.2013.06.001","article-title":"Clinical implementation of adaptive hypofractionated bladder radiotherapy for improvement in normal tissue irradiation","volume":"25","author":"McDonald","year":"2013","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.ijrobp.2024.07.2317_bib0026","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.ijrobp.2010.06.061","article-title":"Online adaptive radiotherapy for muscle-invasive bladder cancer: results of a pilot study","volume":"81","author":"Foroudi","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.07.2317_bib0027","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.radonc.2015.11.003","article-title":"The potential of MRI-guided online adaptive re-optimisation in radiotherapy of urinary bladder cancer","volume":"118","author":"Vestergaard","year":"2016","journal-title":"Radiother Oncol"},{"issue":"5","key":"10.1016\/j.ijrobp.2024.07.2317_bib0028","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.ijrobp.2015.12.379","article-title":"Prospective Study Delivering Simultaneous Integrated High-dose Tumor Boost (<\/=70 Gy) With Image Guided Adaptive Radiation Therapy for Radical Treatment of Localized Muscle-Invasive Bladder Cancer","volume":"94","author":"Hafeez","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.07.2317_bib0029","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.radonc.2009.09.003","article-title":"Lipiodol injection for target volume delineation and image guidance during radiotherapy for bladder cancer","volume":"93","author":"Pos","year":"2009","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2024.07.2317_bib0030","unstructured":"International Commission on Radiation Units and Measurements. ICRU Report 50, Prescribing, recording and reporting photon beam therapy. 1993. Accessed February 19, 2023.https:\/\/www.icru.org\/report\/prescribing-recording-and-reporting-photon-beam-therapy-report-50\/."},{"key":"10.1016\/j.ijrobp.2024.07.2317_bib0031","doi-asserted-by":"crossref","first-page":"20140690","DOI":"10.1259\/bjr.20140690","article-title":"Radiographer-led plan selection for bladder cancer radiotherapy: initiating a training programme and maintaining competency","volume":"88","author":"McNair","year":"2015","journal-title":"Br J Radiol"},{"key":"10.1016\/j.ijrobp.2024.07.2317_bib0032","article-title":"Dose-escalated bladder radiotherapy: Result of first dose cohort","author":"McDonald","year":"2012","journal-title":"National Cancer Research Institute (NCRI) conference"},{"key":"10.1016\/j.ijrobp.2024.07.2317_bib0033","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1200\/jco.2014.32.4_suppl.291","article-title":"Phase I dose-escalated image-guided adaptive bladder radiotherapy study: Results of first dose cohort (68Gy)","volume":"32","author":"Huddart","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.07.2317_bib0034","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.clon.2023.02.003","article-title":"Correlation of clinician- and patient-reported outcomes in the BC2001 trial","volume":"35","author":"Philipps","year":"2023","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.ijrobp.2024.07.2317_bib0035","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/cncr.25667","article-title":"Gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer: Long-term cumulative results of 2 prospective single-institution studies","volume":"117","author":"Caffo","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2024.07.2317_bib0036","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.eururo.2019.11.001","article-title":"Patient-reported quality of life outcomes in patients treated for muscle-invasive bladder cancer with radiotherapy \u00b1 chemotherapy in the BC2001 phase III randomised controlled trial","volume":"77","author":"Huddart","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2024.07.2317_bib0037","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.ijrobp.2016.08.023","article-title":"Quality of life in long-term survivors of muscle-invasive bladder cancer","volume":"96","author":"Mak","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.07.2317_bib0038","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/S1470-2045(19)30790-9","article-title":"International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: Recommendations of the SISAQOL Consortium","volume":"21","author":"Coens","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2024.07.2317_bib0039","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.clon.2019.06.005","article-title":"Adaptive radiotherapy for carcinoma of the urinary bladder: long-term outcomes with dose escalation","volume":"31","author":"Murthy","year":"2019","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.ijrobp.2024.07.2317_bib0040","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.eururo.2011.11.010","article-title":"Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: The MGH experience","volume":"61","author":"Efstathiou","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2024.07.2317_bib0041","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1038\/bjc.2015.109","article-title":"Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder","volume":"112","author":"Hafeez","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijrobp.2024.07.2317_bib0042","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1470-2045(20)30607-0","article-title":"Hypofractionated radiotherapy in locally advanced bladder cancer: An individual patient data meta-analysis of the BC 2001 and BCON trials","volume":"22","author":"Choudhury","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2024.07.2317_bib0043","article-title":"Protocol for tumour-focused dose-escalated adaptive radiotherapy for the radical treatment of bladder cancer in a multicentre phase II randomised controlled trial (RAIDER): radiotherapy planning and delivery guidance","volume":"10","author":"Hafeez","year":"2020","journal-title":"BMJ open"},{"key":"10.1016\/j.ijrobp.2024.07.2317_bib0044","doi-asserted-by":"crossref","first-page":"e251","DOI":"10.1016\/j.clon.2021.02.012","article-title":"Advancing Radiotherapy for Bladder Cancer: Randomised Phase II Trial of Adaptive Image-guided Standard or Dose-escalated Tumour Boost Radiotherapy (RAIDER)","volume":"33","author":"Hafeez","year":"2021","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.ijrobp.2024.07.2317_bib0045","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.ijrobp.2020.12.033","article-title":"Phase 1 trial of atezolizumab plus trimodal therapy in patients with localized muscle-invasive bladder cancer","volume":"110","author":"Marcq","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.07.2317_bib0046","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ijrobp.2023.05.013","article-title":"Efficacy and safety of Bladder Preservation Therapy in combination with Atezolizumab and radiation therapy (BPT-ART) for invasive bladder cancer: Interim analysis from a multicenter, open-label, prospective phase 2 trial","volume":"117","author":"Kimura","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.07.2317_bib0047","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1111\/j.0006-341X.2000.01177.x","article-title":"Sequential designs for phase I clinical trials with late-onset toxicities","volume":"56","author":"Cheung","year":"2000","journal-title":"Biometrics"},{"key":"10.1016\/j.ijrobp.2024.07.2317_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2020.100650","article-title":"Fractional design: An alternative paradigm for late-onset toxicities in oncology dose-finding studies","volume":"19","author":"Yin","year":"2020","journal-title":"Contemp Clin Trials Commun"},{"key":"10.1016\/j.ijrobp.2024.07.2317_bib0049","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00066-003-0976-5","article-title":"The impact of gross tumor volume (GTV) and clinical target volume (CTV) definition on the total accuracy in radiotherapy theoretical aspects and practical experiences","volume":"179","author":"Weiss","year":"2003","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.ijrobp.2024.07.2317_bib0050","doi-asserted-by":"crossref","first-page":"136","DOI":"10.4103\/0971-6203.44472","article-title":"Tumor delineation: The weakest link in the search for accuracy in radiotherapy","volume":"33","author":"Njeh","year":"2008","journal-title":"J Med Phys"},{"key":"10.1016\/j.ijrobp.2024.07.2317_bib0051","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0360-3016(98)00148-5","article-title":"Clinical variability of target volume description in conformal radiotherapy planning","volume":"41","author":"Logue","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.07.2317_bib0052","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0360-3016(02)04162-7","article-title":"Three-dimensional analysis of delineation errors, setup errors, and organ motion during radiotherapy of bladder cancer","volume":"55","author":"Meijer","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.07.2317_bib0053","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.637591","article-title":"MR-guided adaptive radiotherapy for bladder cancer","volume":"11","author":"Hijab","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2024.07.2317_bib0054","first-page":"27","article-title":"Feasibility of tumour-focused adaptive radiotherapy for bladder cancer on the MR-linac","volume":"35","author":"Mitchell","year":"2022","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2024.07.2317_bib0055","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1097\/01.ju.0000093721.23249.c3","article-title":"Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: Results of a urodynamic and quality of life study on long-term survivors","volume":"170","author":"Zietman","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.ijrobp.2024.07.2317_bib0056","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.urology.2004.02.024","article-title":"Prospective quality-of-life assessment in patients receiving concurrent gemcitabine and radiotherapy as a bladder preservation strategy","volume":"64","author":"Herman","year":"2004","journal-title":"Urology"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301624031377?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301624031377?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T23:34:01Z","timestamp":1741649641000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301624031377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0360301624031377"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2024.07.2317","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bladder Tumor-Focused Adaptive Radiation Therapy: Clinical Outcomes of a Phase I Dose Escalation Study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2024.07.2317","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}